#AllergicRhinoconjunctivitis #IgG4 #Allergoid #BirchPollen #Immunotherapy
Allergic rhinoconjunctivitis (ARC) induced by
birch pollen is one of the most common forms of seasonal allergic disease in
Europe. It affects
up to 40% of the population, with a high concentration of
cases in temperate regions where birch trees are prevalent. This condition
presents with a combination of
eye symptoms (conjunctivitis, itching, tearing)
and
nasal symptoms (runny nose, sneezing, congestion), severely impacting
quality of life,
concentration, and
sleep.
Conventional treatments, such as
oral
antihistamines, corticosteroid nasal sprays, and
anti-allergic eye drops, aim
to temporarily relieve symptoms. However,
they do not target the underlying
immunological mechanisms of the disease. Moreover, they
do not prevent the
worsening of the allergy,
the development of new sensitivities, or the
progression to allergic asthma.
Allergen immunotherapy (AIT) is currently
the
only therapeutic option capable of
durably modifying the natural course of ARC.
By gradually exposing the body to the offending allergen, it induces
specific
immune tolerance, notably through the activation of regulatory T cells (Tregs)
and the production of blocking IgG4 antibodies. AIT is therefore recommended
for patients with moderate to severe forms or for those whose symptoms are
poorly controlled by symptomatic treatments.
One of the main obstacles to AIT is the
duration of traditional protocols, which require either
repeated injections
(SCIT) or
prolonged daily intake (SLIT). This often hampers
patient adherence.
As a result, there is growing interest in
shorter, more convenient protocols
that can offer comparable effectiveness.
Allergoids conjugated to mannan
illustrate this progress. By directly targeting dendritic cells, they induce
tolerance more rapidly while reducing the number of necessary injections.
Five injections, a peaceful spring?
For this study, 298 adults allergic to birch pollen were selected. Participants
received five pre-seasonal subcutaneous injections of a mannan-conjugated
allergoid (T502, 10,000 mTU/mL) or a placebo. Effectiveness was measured using
the Combined Symptom and Medication Score (CSMS), quality-of-life
questionnaires (RQLQ), and changes in immunological markers (IgE, IgG, and IgG4
specific to Bet v 1).
The results showed a
33% drop in CSMS in the
T502 group, with a
30.4% reduction in symptoms and a
56.3% decrease in
medication use.
Quality of life improved by 31.5%. Immunologically, there was a
6.2-fold increase in specific IgG4 and
a 62.9% reduction in the IgE/IgG4 ratio,
indicating a shift toward a
tolerant immune response. Additionally, no deaths
or serious adverse events were reported.
Local reactions were mostly
mild and
transient, and
grade I/II systemic reactions affected only
8.1% of patients.
The absence of epinephrine use and the
high completion rate (91%) underscore
the
good tolerability and acceptability of this short protocol.
Excellent tolerability, confirmed efficacy
Birch pollen-induced allergic rhinoconjunctivitis is a common, seasonal
condition that often significantly impairs quality of life during spring. In a
context where symptomatic treatments remain limited, allergen immunotherapy
emerges as a major therapeutic option capable of durably altering disease
progression. However, traditional protocols hinder patient adherence. Against
this backdrop, the study aimed to evaluate the effectiveness and tolerability
of a short-course subcutaneous immunotherapy.
The findings show that this protocol has
significant clinical efficacy. Treated patients experienced
reduced allergic
symptoms, significantly decreased medication use, and
marked improvements in
quality of life. From an immunological perspective, the treatment is associated
with a shift in the immune response toward tolerance.
Tolerability was
excellent, with mostly mild and transient local side effects and a very low
incidence of moderate systemic reactions. No serious adverse events or deaths
were reported.
Although these results clearly support the
potential of a short-course protocol, certain
limitations should be noted. The
study was conducted over a single
pollen season, offering no insight into the
long-term durability of clinical and immunological effects. The long-term
impact of this treatment remains to be confirmed. Furthermore, the pediatric
population was not included, and its effectiveness under
real-life clinical
conditions was not assessed.
Nonetheless, these limitations do not detract
from the
promising potential of this protocol, which is particularly suitable
for patients who are reluctant to commit to prolonged treatments. It could also
be adapted for other seasonal allergies, paving the way for a new generation of
immunotherapies that are more accessible, faster, and better aligned with
patient needs.
Read next: Allergies: could the gut hold the key?
